Geneva, June 4 -- International Clinical Trials Registry received information related to the study (ACTRN12625000511437) titled 'Study to Evaluate the Safety and Pharmacokinetics of M102 in Healthy Participants' on May 23.
Study Type: Interventional
Study Design:
Purpose: Treatment
Allocation: Randomised controlled trial
Masking: Blinded (masking used)
Type of endpoint: Safety
Primary Sponsor: Aclipse One, Inc.
Condition:
Amyotrophic lateral sclerosis (ALS)
Amyotrophic lateral sclerosis (ALS)
Neurological - Neurodegenerative diseases
Intervention:
This is a double-blind, placebo-controlled, ascending dose, multi-cohort trial. The study will be conducted in 2 phases: a single ascending dose (SAD) phase Part A and a multiple ascendi...